NCT06453824View on ClinicalTrials.gov

SAD Evaluation of Safety, Tolerability, PK, and PD of MDI-2517 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

May 17, 2024

Primary Completion Date

November 11, 2024

Study Completion Date

November 11, 2024

Conditions
Safety and Tolerability
Interventions
DRUG

MDI-2517

study drug

OTHER

Placebo

matching placebo

Trial Locations (1)

33136

1951 NW 7th Avenue, Suite 180, Miami

Sponsors
All Listed Sponsors
lead

MDI Therapeutics, Inc.

INDUSTRY

NCT06453824 - SAD Evaluation of Safety, Tolerability, PK, and PD of MDI-2517 in Healthy Participants | Biotech Hunter | Biotech Hunter